Erratum to: 36th International Symposium on Intensive Care and Emergency Medicine

[This corrects the article DOI: 10.1186/s13054-016-1208-6.]

Why do consumers of organic food have more nutritionally balanced diets? – a Danish study

Policies encouraging consumers to follow nutritional dietary guidelines are widely used by governments as a strategy to improve public health. Organic consumers seem to adhere to nutritional guidelines more than others, but it remains obscure why, exactly, there is a correlation between eating healthily and organic consumption. Based on six focus groups, 1519 survey respondents, and purchase data from 2449 households (all data collected in Denmark), we found that not only dedicated but also occasional organic consumers eat more fruit and vegetables and less meat than consumers with no or little organic consumption. We also found that earlier findings on product-level consumption carried over to a meal context, where organic consumers were more likely to substitute some of the meat in their meal with vegetables than non-organic consumers. When respondents were asked about healthy food in general, nutritional health (involving fat, sugar, nutrients) was the dominant health dimension, but the health benefits of organic food were linked to the purity of organic products (e.g. being free-from pesticides, drug residues and artificial additives). We conclude that organic consumption and a nutritionally balanced diet are both driven by an underlying interest in health

Cardioprotective effect of combination therapy by mild hypothermia and local or remote ischemic preconditioning in isolated rat hearts

10.1038/s41598-020-79449-xScientific Reports11126

Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment:A Danish population-based study

Purpose The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission is important information for patients and for planning post-treatment follow-up. The purpose of this study was to evaluate the survival of patients with DLBCL in remission compared with a matched general population. Methods A total of 1,621 patients from the Danish Lymphoma Registry who were newly diagnosed with DLBCL between 2003 and 2011 were included in this study. All patients were ≥ 16 years of age at diagnosis and had achieved complete remission or complete remission unconfirmed after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP–like therapy. Results The 5-year post-treatment DLBCL survival was inferior to survival in the matched general population (78%; 95% CI, 76 to 80; v 87%; standardized mortality ratio, 1.75; P &lt; .001). Excess mortality was present but reduced for patients achieving post-treatment event-free survival for 24 months (pEFS24; standardized mortality ratio, 1.27; P &lt; .001). In age-stratified analyses, the survival of patients &lt; 50 years of age was normalized to the general population after achieving pEFS24 ( P = .99). During the first 8 years after pEFS24, the average loss of lifetime was 0.31 mo/y (95% CI, 0.11 to 0.50 mo/y). Excess mortality diminished when analyzing death from lymphoma as competing event to death from other causes, suggesting that early and late relapse is responsible for increased mortality in patients with DLBCL. Conclusion Although this population-based study does not support complete normalization of survival for patients with DLBCL achieving pEFS24, the estimated loss of residual lifetime was low for patients in continuous remission 2 years after ending treatment. Therefore, pEFS24 is an appealing and relevant milestone for patient counseling and could be a surrogate end point in clinical trials. </jats:sec